Rare Diseases

The Food and Drug Administration has unveiled draft guidance creating a quicker approval pathway for treatments targeting very rare diseases, allowing regulators to green‑light individualized gene and gene‑editing therapies based on a well‑supported, 'plausible mechanism' of action rather than traditional large clinical trials. Announced Monday by Health and Human Services Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary, the policy is aimed at conditions so rare that assembling sizable study populations is nearly impossible, despite clear genetic defects that advanced tools like CRISPR could fix. Officials say the framework was shaped in part by a case at Children’s Hospital of Philadelphia, where doctors used a bespoke gene‑editing therapy to save a Pennsylvania infant with a devastating genetic liver disorder and believe the same template can be adapted repeatedly for similar mutations. Supporters inside and outside FDA, including senior drug‑center officials and Penn scientists, argue the guidance will finally give patients with ultra‑rare conditions a viable regulatory path while still requiring evidence that customized therapies are biologically sound and safe. The move has major implications for U.S. academic hospitals and small biotechs trying to build 'platform' approaches for thousands of rare diseases that now collectively affect an estimated 30 million Americans, and it will reignite debates over how far regulators can bend trial standards without compromising patient protection.